Insoo Park1, Sun-Cheol Park2. 1. Charm Vascular Clinic, Seoul, South Korea. 2. Division of Vascular and Transplant Surgery, Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Abstract
Background: Radiofrequency ablation (RFA) has shown faster recovery and lower pain scores compared to Endovenous laser ablation (EVLA) for treatment of varicose veins. However, a comparison of 1,940-nm EVLA and RFA has not been reported. This study compared short-term outcomes using 1,940-nm EVLA and RFA for varicose veins. Methods: Between April 2018 and June 2018, 43 patients (83 incompetent saphenous veins) were treated with 1,940-nm EVLA and 37 patients (64 incompetent saphenous veins) with RFA. Follow-up duplex was checked at 1 month and 3 months. Results: Baseline characteristics showed no significant differences between both groups except for age. Pain scores at 6 h, and at 1, 10, and 30 days after treatment showed no differences. Complications and time to return to normal activity showed no differences. The 100% closure rate was checked in both groups at 1 month and 3 months follow-up. Conclusion: Short-term outcomes showed no significant differences between 1,940-nm EVLA and RFA treatment.
Background: Radiofrequency ablation (RFA) has shown faster recovery and lower pain scores compared to Endovenous laser ablation (EVLA) for treatment of varicose veins. However, a comparison of 1,940-nm EVLA and RFA has not been reported. This study compared short-term outcomes using 1,940-nm EVLA and RFA for varicose veins. Methods: Between April 2018 and June 2018, 43 patients (83 incompetent saphenous veins) were treated with 1,940-nm EVLA and 37 patients (64 incompetent saphenous veins) with RFA. Follow-up duplex was checked at 1 month and 3 months. Results: Baseline characteristics showed no significant differences between both groups except for age. Pain scores at 6 h, and at 1, 10, and 30 days after treatment showed no differences. Complications and time to return to normal activity showed no differences. The 100% closure rate was checked in both groups at 1 month and 3 months follow-up. Conclusion: Short-term outcomes showed no significant differences between 1,940-nm EVLA and RFA treatment.
Authors: Ian M Nordon; Robert J Hinchliffe; Ranjeet Brar; Paul Moxey; Steve A Black; Matt M Thompson; Ian M Loftus Journal: Ann Surg Date: 2011-12 Impact factor: 12.969
Authors: David Berridge; Andrew W Bradbury; Alun H Davies; Manj Gohel; Isaac Nyamekye; Sophie Renton; Nung Rudarakanchana; Gerry Stansby Journal: Phlebology Date: 2011-04 Impact factor: 1.740
Authors: Martin J C van Gemert; Cees W M van der Geld; Cornelis M A Bruijninckx; Rudolf M Verdaasdonk; H A Martino Neumann Journal: Ann Vasc Surg Date: 2012-08 Impact factor: 1.466
Authors: Peter Gloviczki; Anthony J Comerota; Michael C Dalsing; Bo G Eklof; David L Gillespie; Monika L Gloviczki; Joann M Lohr; Robert B McLafferty; Mark H Meissner; M Hassan Murad; Frank T Padberg; Peter J Pappas; Marc A Passman; Joseph D Raffetto; Michael A Vasquez; Thomas W Wakefield Journal: J Vasc Surg Date: 2011-05 Impact factor: 4.268
Authors: James A Lawson; Stefanie A Gauw; Clarissa J van Vlijmen; Pascal Pronk; Menno T W Gaastra; Marco J Tangelder; Michael C Mooij Journal: J Vasc Surg Venous Lymphat Disord Date: 2017-08-24